RecruitingNCT06806579

Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

1,000 participants

Start Date

Dec 21, 2022

Study Type

OBSERVATIONAL

Conditions

Hepatocellular Carcinoma (HCC)

Summary

\- Background Hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third leading cause of cancer-related death. In most cases (about 80%), HCC develops in a cirrhotic liver - a condition where the liver has been damaged over time, leading to scarring. This makes treatment more challenging. This study will gather and analyze data from patients treated in real-world settings to: 1. Understand the effectiveness and safety of new treatment combinations (e.g., atezolizumab-bevacizumab and durvalumab-tremelimumab). Identify the best treatment sequences for patients with advanced liver cancer. 2. Discover clinical and laboratory markers that predict treatment responses, helping personalize care and optimize outcomes. By addressing these questions, this study will provide valuable information to healthcare providers and guide future treatment decisions for patients with liver cancer.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Hepatocellular carcinoma not amenable to locoregional procedures
Candidate to frontline systemic treatment with atezolizumab-bevacizumab or other immunotherapies

Exclusion Criteria2

Concurrent treatment with other antineoplastic agents
Other active neoplasia

Locations(24)

Ospedali Riuniti Ancona, Via Conca, 71, 60126 Torrette AN

Torrette, AN, Italy

I.R.C.C.S. "S. De Bellis", Via Turi, 27, 70013 Castellana Grotte BA

Castellana Grotte, BA, Italy

AUSL Bologna Via Castiglione 15 40136 Bologna BO

Bologna, BO, Italy

IRCCS Azienda Ospedaliero-Universitaria di Bologna (Oncology Unit), Bologna, BO 40136

Bologna, BO, Italy

IRCCS Azienda Ospedaliero-Universitaria di Bologna (Semiotics Unit)

Bologna, BO, Italy

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, BO, Italy

Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione "Garibaldi, Piazza Santa Maria di Gesù, 5, 95123 Catania CT

Catania, CT, Italy

Ospedali Riuniti. Viale Pinto Luigi, 1, 71122 Foggia FG.

Foggia, FG, Italy

Ospedali Riuniti. Viale Pinto Luigi, 1, 71122 Foggia FG

Foggia, FG, Italy

AOU Careggi. Largo G. Alessandro Brambilla, 3. 50134 Firenze FI

Florence, FI, Italy

Policlinico di Modena Via del Pozzo, 71, 41125 Modena MO

Modena, Missouri, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. via Francesco Sforza, 28 - 20122 Milano.

Milan, MI, Italy

ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore, 3, 20162 Milano

Milan, MI, Italy

Humanitas Research Hospital. Via Alessandro Manzoni, 56, 20089 Rozzano MI

Rozzano, MI, Italy

Azienda Ospedaliero- Universitaria Paolo Giaccone. Via Liborio Giuffrè, 5, 90127 Palermo

Palermo, PA, Italy

Istituto Oncologico Veneto. Via Gattamelata, 64, 35128 Padova PD

Padua, PD, Italy

AOU Pisana. Via Roma 67. 56126 Pisa PI

Pisa, PI, Italy

Ospedale degli Infermi Viale Stradone, 9 48018 Faenza (RA)

Faenza, RA, Italy

IRCCS Santa Maria Nuova Viale Risorgimento, 80, 42123 Reggio Emilia

Reggio Emilia, RE, Italy

Policlinico Gemelli. Largo Agostino Gemelli, 8, 00168 Roma RM

Roma, RM, Italy

Azienda sanitaria universitaria Friuli Centrale, Piazzale Santa Maria della Misericordia, 15 33100 Udine (UD)

Udine, UD, Italy

Azienda Ospedaliera Universitaria Integrata di Verona. Piazzale Aristide Stefani, 1, 37126 Verona VR

Verona, VR, Italy

P.O. Ospedale del Mare. Via Enrico Russo, 11, 80147 Napoli NA

Napoli, Italy

Azienda Ospedaliero- Universitaria Maggiore della Carità, Padiglione G, L.go Bellini, 28100 Novara NO

Novara, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06806579

Related Trials

A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

NCT070522531 location

Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis

NCT074693196 locations

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

NCT0717665051 locations

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

NCT05176483122 locations

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT0729107645 locations